Canadian court loss exposes AstraZeneca to generic Nexium risk
This article was originally published in Scrip
Executive Summary
AstraZeneca has said that it is "evaluating its options" after a Canadian court ruling has increased the chances of approval for Apotex's generic version of the company's gastrointestinal disorder treatment Nexium (esomeprazole magnesium).